Project Grant K99AI193247
Award Date 8/11/25
Completion Date 7/31/27
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $136,104 Project Grant to Tufts University School of Medicine. The grant, awarded on October 24, 2025, will support research to investigate the effect of Clostridioides difficile's (C. difficile) spatial distribution and toxin gene expression within the colon on disease severity. The research will utilize fluorescent reporter strains...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $171,254 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Nimml Institute Inc., a 501(c)(3) non-profit research organization in Blacksburg, Virginia. The grant, effective from December 1, 2024 to November 30, 2026, aims to elucidate novel immunometabolic mechanisms that intercept bacterial toxin internalization and processing to suppress cell damage caused by Clostridioides difficile...
- This Project Grant award of $2,872,722 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to elucidate the role of penicillin-binding proteins (PBPs) in the Clostridioides difficile life cycle and develop new PBP inhibitors to target C. difficile sporulation. The research aims to enhance the understanding of PBPs across bacterial species and provide new insights into the unique...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $521,030.00 to the University of North Carolina at Chapel Hill to conduct research on the role of phenotypic heterogeneity in the fitness of Clostridioides difficile, a leading cause of antibiotic-associated disease. The goal is to define the interplay between stochastic and regulatory mechanisms underlying the...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) is supporting research to develop a novel, water-soluble, cationic bolaamphiphile (CAB) platform nanocarrier complexed with an antisense oligonucleotide (ASO) targeting the essential C. difficile dnaE gene. The $426,875 award, which began on Jul 14, 2025 and runs through Jun 30, 2027, aims to advance this platform technology as a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 SBIR Phase 1 project grant to Biotherapeutics, Inc. under the Allergy and Infectious Diseases Research program (CFDA 93.855). The goal of the project is to develop a novel, host-targeted, antibiotic-sparing oral therapeutic for concomitant Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD). The specific aims are to: 1) Compare the efficacy of the novel oral immunoregulatory therapeutic...
- This is a $300,892 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by the University of North Carolina at Chapel Hill to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in Clostridioides difficile. The objective is to determine how these factors regulate the expression of key virulence genes involved in C. difficile...
- This $661,693 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to define the structure and function of a new family of peptidoglycan crosslinking enzymes in the opportunistic pathogen Clostridioides difficile. The research aims to advance understanding of C. difficile's cell wall composition and enzymes essential for its survival and virulence, with the potential to inform the...
- This $780,162 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Old Dominion University from August 2022 through July 2026 exploring the role of nutrient and stress sensing in regulating Clostridioides difficile physiology and behavior within the host. The research aims to determine how the stringent response regulates disease-relevant bacterial processes and characterize enzymes that mediate alarmone metabolism...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $754,446 to the University of Tennessee Health Science Center to develop novel microbiome-sparing antibacterial treatments for Clostridioides difficile infection (CDI). The key objectives are to: 1) optimize lead inhibitor compounds targeting the bacterial enzyme FABK to improve antimicrobial potency;...